{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:18:35Z","timestamp":1790036315582,"version":"4.0.1"},"reference-count":47,"publisher":"Wiley","issue":"s2","license":[{"start":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T00:00:00Z","timestamp":1356652800000},"content-version":"vor","delay-in-days":27,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Metabolism Res"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>It has long been known that antihypertensive drugs may affect blood glucose in a differential manner. In particular new onset diabetes is significantly increased in association with the use of thiazides or beta\u2010blockers, respectively, compared to placebo, whereas treatment with angiotensin\u2010conversion\u2010enzyme\u2010inhibitors or angiotensin\u2010receptor\u2010blockers is associated with a lower than expected frequency, as also assessed in several meta\u2010analyses. In line with these notions, the NAVIGATOR Trial was the first to report a significant preventive effect of an angiotensin\u2010receptor\u2010blocker on new onset diabetes evaluated as a primary outcome in a prospective randomized study. Hence, and in view of the fact that comparable blood pressure lowering with any of the five major classes of antihypertensive drugs, including calcium\u2010channel\u2010blockers, give comparable benefits in reducing cardiovascular complications, unless there are specific indications or contraindications for an individual drug, caution should be exercised, therefore, to use beta\u2010blockers or thiazides as first\u2010line drugs for blood pressure lowering indications in subjects at high risk to develop diabetes, especially in patients with so called metabolic syndrome. The potential of glycemic worsening in overt diabetic patients with thiazides or beta\u2010blockers has less well been studied systematically, yet paradigmatically in UKPDS evaluating a randomized comparison of a beta\u2010blocker with an angiotensin\u2010conversion\u2010enzyme(ACE)\u2010inhibitor. Not only was there HbA1c worsening with beta\u2010blocker use which required additional blood glucose lowering therapy, but also significantly more weight gain which still was detectable at the 20\u2003year follow\u2010up. On the other hand, the overall cardiovascular outcomes were comparable in the two treatment groups irrespective whether therapy was based on the beta blocker atenolol or the ACE\u2010inhibitor captopril<jats:styled-content>.<\/jats:styled-content> Awareness of these facts and highly individualized therapy seem to be the way forward.<\/jats:p>","DOI":"10.1002\/dmrr.2355","type":"journal-article","created":{"date-parts":[[2012,12,28]],"date-time":"2012-12-28T10:58:57Z","timestamp":1356692337000},"page":"60-66","source":"Crossref","is-referenced-by-count":14,"title":["What should be the antihypertensive drug of choice in diabetic patients and should we avoid drugs that increase glucose levels? Pro and Cons"],"prefix":"10.1002","volume":"28","author":[{"given":"Eberhard","family":"Standl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Erbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,12,28]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250051556"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm124"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc07-2124"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-0680"},{"key":"e_1_2_8_6_2","unstructured":"International Diabetes Federation.Diabetes atlas.http:\/\/www idf org\/diabetesatlas 2009Accessed 16 August 2011."},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60108-1"},{"key":"e_1_2_8_8_2","unstructured":"StandlE.Effects of hydrochlorothiazide on the serum insulin concentrations of dogs after intravenous glucose tolerance test. Doctor\u2019s thesis (inaugural dissertation) 1967."},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004872-200306000-00002"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b1665"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002003.pub2"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007185.pub2"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.23.2981"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2004.08.059"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000125726.92964.ab"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc06-1373"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcg123"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1821"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903533681"},{"key":"e_1_2_8_20_2","article-title":"Effect of valsartan on the incidence of diabetes and cardiovascular events","author":"The Navigator Study Group","year":"2010","journal-title":"N Engl J Med"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065061"},{"key":"e_1_2_8_22_2","first-page":"93","article-title":"Reduction in the incidence of type 2 diabetes with life style intervention or metformin","volume":"346","author":"Diabetes Prevention Program Research Group","year":"2002","journal-title":"N Engl J Med"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08905-5"},{"key":"e_1_2_8_24_2","article-title":"Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial","author":"DREAM Investigators","year":"2006","journal-title":"Lancet"},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1010949"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_8_27_2","first-page":"997","article-title":"The effect of intensive treatment of diabetes on the development and progression of longterm complications of insulin\u2010dependent diabetes mellitus","volume":"329","author":"The Diabetes Control, Complication Trial Research Group","year":"1993","journal-title":"N Engl J Med"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60697-8"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-009-1470-0"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.16.2159"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021778"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706245"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-5491.1994.tb00352.x"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s001250050614"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.317.7160.703"},{"key":"e_1_2_8_37_2","first-page":"317","article-title":"Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39","author":"UK Prospective Diabetes Study Group","year":"1998","journal-title":"Brit Med J"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806359"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61303-8"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-008-1179-5"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2010.04.024"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806182"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.02.046"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39548.738368.BE"},{"key":"e_1_2_8_45_2","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD008161","article-title":"First\u2010line drugs for hypertension","author":"Wright JM","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_46_2","first-page":"CD\u2013003658","article-title":"Calcium channel blockers versus other classes of drugs for hypertension","volume":"4","author":"Chen N","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(03)00158-X"},{"key":"e_1_2_8_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80152-1"}],"container-title":["Diabetes\/Metabolism Research and Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fdmrr.2355","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dmrr.2355","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T13:32:25Z","timestamp":1694611945000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/dmrr.2355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":47,"journal-issue":{"issue":"s2","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["10.1002\/dmrr.2355"],"URL":"https:\/\/doi.org\/10.1002\/dmrr.2355","archive":["Portico"],"relation":{},"ISSN":["1520-7552","1520-7560"],"issn-type":[{"value":"1520-7552","type":"print"},{"value":"1520-7560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}